Amgen Foresees a Loss: Amgen expects to...

Amgen Foresees a Loss: Amgen expects to lose between $8 million and $9 million for its fiscal year that ended March 31. The Thousand Oaks biotechnology firm attributed the results to a delay by the U.S. Food and Drug Administration in approving the sale of Amgen’s anti-anemia drug, erythropoietin, or EPO. The company expected FDA approval last month and had invested heavily in marketing and production costs to sell the drug. But last week a federal judge ordered Amgen to amend its drug application with the FDA, and the company said it doesn’t know how long it will be before it receives FDA approval to sell the drug.